Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides

被引:45
作者
Ferreiro, MG
Tillman, LG
Hardee, G
Bodmeier, R
机构
[1] Free Univ Berlin, Coll Pharm, D-12169 Berlin, Germany
[2] ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA
关键词
antisense oligonucleotide; alginate; poly-L-lysine; permeation enhancer; microparticles; intestinal absorption;
D O I
10.1023/A:1016188312399
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. A microparticle carrier based on alginate and poly-L-lysine was developed and evaluated for the delivery of antisense oligonucleotides at the intestinal site. Formulations of oligonucleotide-loaded microparticles having differences in the carrier molecular weight and composition were characterized in vitro and in vivo. Methods. Polymeric microparticles were prepared by ionotropic gelation and crosslinking of alginate with calcium ions and poly-L-lysine. The loading of the antisense oligonucleotide into the microparticles was achieved by absorption in aqueous medium. The association capacity, loading and particle size of the microparticles were characterized. The in vivo performances of various formulations after intrajejunal administration were studied in rat and in dog models. Results. Microparticles had a sponge-like structure and an oligonucleotide loading of 27-35%. The composition of the medium affected the particle size and the in vitro release profiles. The oligonucleotide bioavailability after intrajejunal administration to rats in the presence of permeation enhancers was good for most of the tested systems. The application of microparticles in powder form compared to an equivalent suspension improved the intrajejunal bioavailability of the oligonucleotide (25% and 10% respectively) in rats. On the contrary, the intrajejunal administration to dogs resulted in poor oligonucleotide bioavailability (0.42%). Conclusions. The formulation of antisense oligonucleotides within alginate and poly-L-lysine microparticles is a promising strategy for the oral application.
引用
收藏
页码:755 / 764
页数:10
相关论文
共 27 条
[1]   The delivery of antisense therapeutics [J].
Akhtar, S ;
Hughes, MD ;
Khan, A ;
Bibby, M ;
Hussain, M ;
Nawaz, Q ;
Double, J ;
Sayyed, P .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21
[2]   Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides [J].
Aynié, I ;
Vauthier, C ;
Chacun, H ;
Fattal, E ;
Couvreur, P .
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1999, 9 (03) :301-312
[3]   Pharmacokinetics in mice of a [H-3]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid [J].
Bennett, CF ;
Zuckerman, JE ;
Kornbrust, D ;
Sasmor, H ;
Leeds, JM ;
Crooke, ST .
JOURNAL OF CONTROLLED RELEASE, 1996, 41 (1-2) :121-130
[4]   Oral vaccination of animals with antigens encapsulated in alginate microspheres [J].
Bowersock, TL ;
HogenEsch, H ;
Suckow, M ;
Guimond, P ;
Martin, S ;
Borie, D ;
Torregrosa, S ;
Park, H ;
Park, K .
VACCINE, 1999, 17 (13-14) :1804-1811
[5]   Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines [J].
Brayden, DJ ;
O'Mahony, DJ .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (07) :291-299
[6]  
Butler M, 1997, LAB INVEST, V77, P379
[7]   Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue [J].
Butler, M ;
Stecker, K ;
Bennett, CF .
NUCLEOSIDES & NUCLEOTIDES, 1997, 16 (7-9) :1761-1764
[8]  
Cook PD, 1998, HANDB EXP PHARM, V131, P51
[9]  
Crooke R.M., 1993, ANTISENSE RES APPL, P427
[10]   Cationic polymer based gene delivery systems [J].
De Smedt, SC ;
Demeester, J ;
Hennink, WE .
PHARMACEUTICAL RESEARCH, 2000, 17 (02) :113-126